Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05540522 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 45,789
- Enrollment target
NCT05540522 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 45,789 participants.
The verdict
NCT05540522, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45,789 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
Interventions
- BIOLOGICAL Quadrivalent influenza modRNA vaccine
- BIOLOGICAL Quadrivalent influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45,789 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2024-03-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05540522
The ClinicalTrials.gov registry entry for NCT05540522 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45,789 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quadrivalent influenza modRNA vaccine is the first listed.
NCT05540522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05540522 about?
NCT05540522 is a clinical study titled "A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older". This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
What is the current status of trial NCT05540522?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45,789 participants. The study started on 2022-09-12. Estimated completion is 2024-03-12.
What interventions are being tested in trial NCT05540522?
The interventions under investigation include: Quadrivalent influenza modRNA vaccine (BIOLOGICAL), Quadrivalent influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05540522?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.